Jai V. Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jai V. Patel has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Alain Sadoun
Transgene, Illkirch-Graffenstaden, France
14 shared publications - Cristina Smolenschi
Institut Gustave Roussy, Villejuif, France
14 shared publications - Emma J. West
Leeds Institute of Medical Research at St. James’s, University of Leeds, Leeds, United Kingdom
14 shared publications - Kaidre Bendjama
NEC Bio B.V., Netherlands
14 shared publications - Marta Kurzawa
Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
14 shared publications - Philippe Alexandre Cassier
Centre Léon Bérard, Lyon, France
14 shared publications
Latest Publications
- 1 September 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 83 (5) , 915-920
Proceedings of ESPGHAN monothematic conference 2024 (II): Management of portal hypertension in children and adolescents
Objective: To summarise current evidence and expert perspectives on the management of paediatric portal hypertension, primarily focusing on portal hypertensive varices and gastrointestinal bleeding in children, as discussed during the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) monothematic conference meeting on portal hypertension. Methods: In 2024, an EPSGHAN 3‐day monothematic conference on paediatric portal hypertension was held in Dublin (Ireland), gathering international experts in portal hypertension. The second part of the meeting focused on clinical algorithms for acute variceal bleeding, minimally invasive radiological treatments, surgical shunts, and indications for liver transplantation. Additional sessions examined methodological constraints affecting paediatric clinical trials, supported by case‐based discussions and expert panel debates. Results: Faculty outlined updated approaches to emergency management for upper gastrointestinal bleeding, including stabilisation, pharmacotherapy and endoscopy treatment. Minimally invasive radiological procedures and surgical treatments were reviewed. Sessions highlighted indications for transplantation and management of post‐transplant portal vein thrombosis. Presentations on registries underscored their value in rare diseases. The final session detailed the statistical, ethical and logistical challenges inherent in paediatric clinical trials and specific challenges in portal hypertension trials. Conclusions: Current management strategies across medical, endoscopic, radiological and surgical fields were reviewed, recognising the scarcity of paediatric‐specific evidence. Enhanced collaboration, harmonised registries, and standardised study designs were identified as vital next steps towards optimising outcomes in children with portal hypertension.
- 1 September 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 83 (5) , 915-920
Proceedings of ESPGHAN monothematic conference 2024 (II): Management of portal hypertension in children and adolescents
Objective: To summarise current evidence and expert perspectives on the management of paediatric portal hypertension, primarily focusing on portal hypertensive varices and gastrointestinal bleeding in children, as discussed during the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) monothematic conference meeting on portal hypertension. Methods: In 2024, an EPSGHAN 3‐day monothematic conference on paediatric portal hypertension was held in Dublin (Ireland), gathering international experts in portal hypertension. The second part of the meeting focused on clinical algorithms for acute variceal bleeding, minimally invasive radiological treatments, surgical shunts, and indications for liver transplantation. Additional sessions examined methodological constraints affecting paediatric clinical trials, supported by case‐based discussions and expert panel debates. Results: Faculty outlined updated approaches to emergency management for upper gastrointestinal bleeding, including stabilisation, pharmacotherapy and endoscopy treatment. Minimally invasive radiological procedures and surgical treatments were reviewed. Sessions highlighted indications for transplantation and management of post‐transplant portal vein thrombosis. Presentations on registries underscored their value in rare diseases. The final session detailed the statistical, ethical and logistical challenges inherent in paediatric clinical trials and specific challenges in portal hypertension trials. Conclusions: Current management strategies across medical, endoscopic, radiological and surgical fields were reviewed, recognising the scarcity of paediatric‐specific evidence. Enhanced collaboration, harmonised registries, and standardised study designs were identified as vital next steps towards optimising outcomes in children with portal hypertension.
- 1 September 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 83 (5) , 906-914
Proceedings of ESPGHAN monothematic conference 2024 (I): Aetiology, diagnosis and complications of portal hypertension in children and adolescents
Objectives: The hepatology committee of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) aims to provide education on key aspects of paediatric hepatology. Here we provide recent developments in the understanding, diagnosis and clinical consequences of portal hypertension (PHT) in children and young people, an area in which evidence remains scarce and fragmented. Methods: In 2024, an EPSGHAN 3‐day monothematic conference on paediatric PHT, held in Dublin (Ireland), brought together international experts in PHT. The first sessions of the conference were dedicated to PHT classification, pathophysiology, epidemiology, diagnostic dilemmas and major complications. Lectures have been integrated to provide an up‐to‐date overview of clinical practice. Results: Opening sessions addressed the definition and classification of paediatric PHT, highlighting key differences between cirrhotic and non‐cirrhotic causes. Advances in diagnostic imaging, the role of non‐invasive tests and biopsy limitations are reviewed. Subsequent discussions focused on the mechanisms and management of major complications, including renal impairment, encephalopathy, cardiopulmonary dysfunction and endocrine consequences. Nutritional challenges and the interaction between PHT and gut‐liver axis were emphasised as possible determinants of outcomes. Conclusions: This report summarises the key learning points of the first part of the meeting. These discussions set the foundation for defining research priorities and improving early recognition and multidisciplinary care strategies.
- 1 September 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 83 (5) , 906-914
Proceedings of ESPGHAN monothematic conference 2024 (I): Aetiology, diagnosis and complications of portal hypertension in children and adolescents
Objectives: The hepatology committee of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) aims to provide education on key aspects of paediatric hepatology. Here we provide recent developments in the understanding, diagnosis and clinical consequences of portal hypertension (PHT) in children and young people, an area in which evidence remains scarce and fragmented. Methods: In 2024, an EPSGHAN 3‐day monothematic conference on paediatric PHT, held in Dublin (Ireland), brought together international experts in PHT. The first sessions of the conference were dedicated to PHT classification, pathophysiology, epidemiology, diagnostic dilemmas and major complications. Lectures have been integrated to provide an up‐to‐date overview of clinical practice. Results: Opening sessions addressed the definition and classification of paediatric PHT, highlighting key differences between cirrhotic and non‐cirrhotic causes. Advances in diagnostic imaging, the role of non‐invasive tests and biopsy limitations are reviewed. Subsequent discussions focused on the mechanisms and management of major complications, including renal impairment, encephalopathy, cardiopulmonary dysfunction and endocrine consequences. Nutritional challenges and the interaction between PHT and gut‐liver axis were emphasised as possible determinants of outcomes. Conclusions: This report summarises the key learning points of the first part of the meeting. These discussions set the foundation for defining research priorities and improving early recognition and multidisciplinary care strategies.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
Patient demographics and disease summary
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
Patient demographics and disease summary
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
Detection of TG6002, nAb, 5-FC, 5-FU, and F-BAL in plasma following treatment. A, Plasma samples analyzed by qPCR to detect TG6002 following treatment. Values stated are the number of copies per milliliter (c/mL). B, Serum nAb titers (IC50) for n = 15 patients, sample availability–dependent. * P < 0.05, paired t test. C, Serum 5-FC, 5-FU, and F-BAL concentrations at day 8 following treatment (n = 13 patients), sample availability–dependent. Cohort 1: purple, cohort 2: green, cohort 3: blue, and cohort 4: red. BLD, below limit of detection; BLQ, below the limit of quantification; C, cycle; D, day; nAb, neutralizing antibody; ND, not done due to insufficient sample.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
Detection of TG6002, nAb, 5-FC, 5-FU, and F-BAL in plasma following treatment. A, Plasma samples analyzed by qPCR to detect TG6002 following treatment. Values stated are the number of copies per milliliter (c/mL). B, Serum nAb titers (IC50) for n = 15 patients, sample availability–dependent. * P < 0.05, paired t test. C, Serum 5-FC, 5-FU, and F-BAL concentrations at day 8 following treatment (n = 13 patients), sample availability–dependent. Cohort 1: purple, cohort 2: green, cohort 3: blue, and cohort 4: red. BLD, below limit of detection; BLQ, below the limit of quantification; C, cycle; D, day; nAb, neutralizing antibody; ND, not done due to insufficient sample.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Table 2 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
AEs summarized by relationship to TG6002 and 5-FC.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
AEs summarized by relationship to TG6002 and 5-FC.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
Detection of TG6002 in patient tumor biopsies. A, Table summary of data collated from assays to detect the presence of TG6002 in tumor biopsies: qPCR and qRT-PCR to detect viral nucleic acids, plaque assay to detect replication-competent virus (infectious virus particles per biopsy), IHC to determine the presence of virus protein, and 5-FU (pg/mg) to demonstrate transgene activity. Samples are designated as either positive or negative/below the limit of detection for each assay. B, Representative examples of positively stained tumor cells by IHC for patients 04 (day 4) and 06 (day 8) (left; brown DAB) and negative control (right; secondary antibody alone). Scale bars, 200 μm. BLQ, below the limit of quantification; D4, day 4; D8, day 8; ND, not done due to insufficient sample; NP, not planned.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
Detection of TG6002 in patient tumor biopsies. A, Table summary of data collated from assays to detect the presence of TG6002 in tumor biopsies: qPCR and qRT-PCR to detect viral nucleic acids, plaque assay to detect replication-competent virus (infectious virus particles per biopsy), IHC to determine the presence of virus protein, and 5-FU (pg/mg) to demonstrate transgene activity. Samples are designated as either positive or negative/below the limit of detection for each assay. B, Representative examples of positively stained tumor cells by IHC for patients 04 (day 4) and 06 (day 8) (left; brown DAB) and negative control (right; secondary antibody alone). Scale bars, 200 μm. BLQ, below the limit of quantification; D4, day 4; D8, day 8; ND, not done due to insufficient sample; NP, not planned.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
Trial schema and sampling schedule. A, Trial schema depicting treatment schedule of two planned cycles of IHA TG6002 and oral 5-FC. B, Patient blood and tissue samples taken at various time points prior to and during treatment. Blood samples were specific for downstream analyses: translational (red), pharmacokinetic (blue), pharmacodynamic (green), neutralizing antibody (purple), and tissue biopsies (black). SC, screening; BS, baseline; C, cycle; D, day. (Created with BioRender.com.)
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
Trial schema and sampling schedule. A, Trial schema depicting treatment schedule of two planned cycles of IHA TG6002 and oral 5-FC. B, Patient blood and tissue samples taken at various time points prior to and during treatment. Blood samples were specific for downstream analyses: translational (red), pharmacokinetic (blue), pharmacodynamic (green), neutralizing antibody (purple), and tissue biopsies (black). SC, screening; BS, baseline; C, cycle; D, day. (Created with BioRender.com.)
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
MRNA sequencing of patient PBMCs revealing clustering of DEGs involved in immune activation and response pathways to treatment. A, The number of upregulated ssDEGs in the post-treatment samples relative to pretreatment controls for days 2 and 15 post-infusion. B, Volcano plots for three patients that highlight nine commonly expressed ssDEGs (red: downregulated DEGs, blue: upregulated DEGs, black: nonsignificant changes to DEGs, and green: specific highlighted ssDEGs). C, Cluster plot of the nine commonly expressed ssDEGs in three patients which correspond to (D) immune-related GO pathways. E, GO analysis showing cluster plots of all upregulated ssDEGs in three patients at days 2 and 15. DEGs are defined as up-/downregulated from baseline, Padj < 0.05; ssDEGs are defined as ± >2 log2 fold change and Padj < 0.05.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
MRNA sequencing of patient PBMCs revealing clustering of DEGs involved in immune activation and response pathways to treatment. A, The number of upregulated ssDEGs in the post-treatment samples relative to pretreatment controls for days 2 and 15 post-infusion. B, Volcano plots for three patients that highlight nine commonly expressed ssDEGs (red: downregulated DEGs, blue: upregulated DEGs, black: nonsignificant changes to DEGs, and green: specific highlighted ssDEGs). C, Cluster plot of the nine commonly expressed ssDEGs in three patients which correspond to (D) immune-related GO pathways. E, GO analysis showing cluster plots of all upregulated ssDEGs in three patients at days 2 and 15. DEGs are defined as up-/downregulated from baseline, Padj < 0.05; ssDEGs are defined as ± >2 log2 fold change and Padj < 0.05.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Figure 6 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
Adaptive T-cell responses to treatment. T-cell function was assessed by ELISpot assay, which showed an IFNγ-release response to CEA and TG6002. A, Data expressed as the mean fold change ± SEM SFU of post-treatment samples compared with baseline. n = 6 patients, sample availability–dependent. B, Representative examples of SFU from two patients showing BS and post-treatment samples, in triplicate, depicting responses to CEA and TG6002. C and D, TCRβ sequencing examined the T-cell clonal response to TG6002 infusion. CDR3 sequences were matched to known TCRs using the McPAS database. TCRs matched to cancer antigen epitopes (C) and neoantigen epitopes (D) are shown; data are expressed as number of total matched TCRs (x-axis) vs. the sum of productive frequencies of matched TCRs (y-axis). Cohort 1; purple, cohort 2: green, and cohort 3: blue. SFU, spot-forming units; CDR3, complementary-determining region 3; BS, baseline.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
Adaptive T-cell responses to treatment. T-cell function was assessed by ELISpot assay, which showed an IFNγ-release response to CEA and TG6002. A, Data expressed as the mean fold change ± SEM SFU of post-treatment samples compared with baseline. n = 6 patients, sample availability–dependent. B, Representative examples of SFU from two patients showing BS and post-treatment samples, in triplicate, depicting responses to CEA and TG6002. C and D, TCRβ sequencing examined the T-cell clonal response to TG6002 infusion. CDR3 sequences were matched to known TCRs using the McPAS database. TCRs matched to cancer antigen epitopes (C) and neoantigen epitopes (D) are shown; data are expressed as number of total matched TCRs (x-axis) vs. the sum of productive frequencies of matched TCRs (y-axis). Cohort 1; purple, cohort 2: green, and cohort 3: blue. SFU, spot-forming units; CDR3, complementary-determining region 3; BS, baseline.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
AEs summarized by relationship to grade.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
AEs summarized by relationship to grade.